Identification of the PRRX1-TOP2A interaction as one of the mechanisms involved in tumour malignancy has clarified the pathophysiological background of MPNST and raised the prospect of developing novel therapeutic strategies for malignant tumours with poor prognosis, including MPNST. This evidence concerns the gene TOP2A and neoplasm.